MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Deciphera Pharmaceuticals, LLC100 enrolled

Overview

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Tenosynovial Giant Cell Tumor

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of TGCT according to medical records 2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated. 3. Has provided informed consent and medical records release Exclusion Criteria: 1\. Participant is active in an interventional clinical trial of vimseltinib

Locations (1)

Synexus Clinical Research, US INC

Wilmington, North Carolina, United States

RECRUITING

Outcomes

Primary Outcomes

Duration of Vimseltinib Treatment

Time frame: Baseline up to 12 months

Time to Discontinuation of Vimseltinib

Time frame: Baseline to Discontinuation (Estimated up to 12 months)

Central Contacts

Clinical Team

CONTACT

888-724-3274 clinicaltrials@deciphera.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.